Shortage of Pancreatic enzyme replacement therapy (PERT) - Additional actions
Supplements NatPSA/2024/007/DHSC. Continued limited Creon supplies through 2026.
Source · National Patient Safety Alerts
HOUNSLOW AND RICHMOND COMMUNITY HEALTHCARE NHS TRUST
RY9 ODS code
LONDON region
11 open alerts
2 Sep 2026 CAS snapshot
National Patient Safety Alerts recorded as open for this trust after their completion deadline had passed, drawn from the MHRA Central Alerting System compliance report of 2 September 2026. That report names only organisations past a deadline, so it records neither compliance nor the position since that snapshot.
Open alerts for this trust
Discontinuation of Promixin (colistimethate) 1-million unit powder for nebuliser solution unit dose vials
Promixin colistimethate inhalation powder phased out May 2025. Ensure continuity of care.
Shortage of bumetanide 1mg tablets
Bumetanide 1mg tablets stock depletion through mid-August 2025. Furosemide available as alternative.
Shortage of Antimicrobial Agents Used in Tuberculosis (TB) Treatment
Potential contamination of non-sterile alcohol-free skin cleansing wipes with Burkholderia spp: measures to reduce patient risk
UK-wide Burkholderia stabilis outbreak linked to contaminated skin cleansing wipes.
Supply of Licensed and Unlicensed Epidural Infusion Bags
Epidural bag supply issues from Sandoz and Fresenius Kabi expected until at least March 2026.
Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited due to a potential for overdosing
Quetiapine oral suspension contains double the intended active ingredient (166 units, Oct 2025-Jan 2026). Cease distribution.
Steriflex No. 109 (1L) and No. 171 (2L): Potassium Chloride 0.15%, Sodium Chloride 0.45%, Glucose 2.5% Bags
Fresenius Kabi transitioning to DEHP-free IV bags with supply shortages through September 2026.
Harm from delayed administration of rasburicase for tumour lysis syndrome
Prevent delays in administering rasburicase for tumour lysis syndrome. Ideally given within one hour in high-risk cases.
Shortage of dinoprostone 3mg vaginal tablets and 1mg/2.5ml, 2mg/2.5ml vaginal gel
Risk associated with adult breathing circuits lacking a patent exhalation route
Develop local guidance for assembling breathing circuits, implement staff training on safety checks.
Data source
Data from the MHRA Central Alerting System compliance report of 2 September 2026, which lists alerts that had passed their completion deadline and remained open at that date. The Central Alerting System does not publish a list of compliant organisations, and the report says nothing about the position since that snapshot.